The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intergroup ALFA/GOELAMS randomized phase II trial of lirilumab anti-KIR monoclonal antibody (IPH2102/BMS986015) as maintenance treatment in elderly patients with acute myeloid leukemia (EFFIKIR trial).
Norbert Vey
Honoraria - Bristol-Myers Squibb; Innate Pharma
Hervé Dombret
No relevant relationships to disclose
Norbert Ifrah
No relevant relationships to disclose
Arnaud Pigneux
No relevant relationships to disclose
Claude Gardin
No relevant relationships to disclose
Marc E. Buyse
Employment or Leadership Position - IDDI
Stock Ownership - IDDI
Pascale Andre
Employment or Leadership Position - Innate Pharma
Stock Ownership - Innate Pharma
Anne Tirouvanziam-Martin
Employment or Leadership Position - Innate Pharma
Stock Ownership - Innate Pharma
Robert Albert Zerbib
Employment or Leadership Position - Innate Pharma
Stock Ownership - Innate Pharma
Renaud Buffet
Employment or Leadership Position - Innate Pharma
Stock Ownership - Cytheris
Marcel Rozencweig
Employment or Leadership Position - Innate Pharma
Stock Ownership - Innate Pharma